Fusion inhibitors are a type of antiviral drug used to treat HIV infections. They are a class of antiretroviral drugs that work by blocking the fusion of HIV with the host cell membrane, preventing the virus from entering the cell. Fusion inhibitors are an important part of combination antiretroviral therapy (cART) and are often used in combination with other antiretroviral drugs.
Fusion inhibitors are generally used in combination with other antiretrovirals, such as reverse transcriptase inhibitors and protease inhibitors. The combination of drugs is known as highly active antiretroviral therapy (HAART). HAART is the most effective form of treatment for HIV and is the standard of care for HIV-positive individuals. Fusion inhibitors work by targeting the HIV envelope glycoproteins (Env). Env is a protein located on the surface of the virus that is responsible for binding to the host cell membrane and allowing the virus to enter the cell. Fusion inhibitors bind to Env and block its ability to bind to the host cell membrane, preventing the virus from entering the cell.

Know More- https://www.globalinsightservices.com/reports/fusion-inhibitors-market/

Market Segments
The fusion inhibitors market can be segmented by route of administration, indication, distribution channel, and region. By route of administration, the market can be divided into parenteral and oral. By indication, the market can be divided into HIV/AIDS, and COVID-19. By distribution channel, the market can be divided into retail pharmacies, online pharmacies, and other services. By region, the market is divided into North America, Europe, Asia-Pacific, and the Rest of the World.

Key Players
The fusion inhibitors market includes players such as Bristol-Myers Squibb Company(US), Incyte(US), AstraZeneca(UK), ViiV Healthcare Limited(UK), Frontier Biotechnologies(CN), Trimeris, Inc(US), Progenics Pharmaceuticals(US), Schering-Plough (Merck & Co(US), Biogen(US), and Vanderbilt University(US), among others.